Explanipedia

GABAergic regulation of action-outcome priors in conditions associated with frontotemporal degeneration Open

R Williams, Michelle Naessens, Emily Todd, Rory Durcan, David J. Whiteside , et al. · 2025

Rationale Apathy is a common symptom in many neurological and psychiatric conditions, associated with poor prognosis and increased caregiver burden. There are currently no proven treatments, in part due to a lack of mechanistic understandi…

Changes in DTI-ALPS index and its associations with neuronal damage in Lewy body disease Open

Michael Firbank, Paul C. Donaghy, Louise Allan, Nicola Barnett, Sally Barker , et al. · 2025

DTI-ALPS is reduced in DLB compared to healthy comparators. Our findings suggest that dysfunction of the glymphatic system may contribute to neuronal damage in Lewy body disease. However further research is needed to clarify the role of th…

Inflammation PET and plasma neurofilament light predict survival in people with progressive supranuclear palsy Open

Noah Lorenz Shapiro, P. Simon Jones, Elijah Mak, Kamen A. Tsvetanov, Julia Goddard , et al. · 2025

Progressive Supranuclear Palsy (PSP) is a primary tauopathy characterised by atrophy and neuroinflammation of the brainstem, basal ganglia and, to a lesser degree of the cortex. This study investigates the association of regional atrophy (…

Cross-sectional and longitudinal associations between depressive symptoms and cognitive performance in mild cognitive impairment Open

Calum A. Hamilton, Paul C. Donaghy, John‐Paul Taylor, Joanna Ciafone, Rory Durcan , et al. · 2025

Background Depressive symptoms are common in mild cognitive impairment (MCI). These may be associated with poorer cognitive function and increased risks of dementia transition. Aims We aimed to examine the cognitive patterns associated wit…

Plasma Biomarkers and Disease Prognosis in Mild Cognitive Impairment with Lewy Bodies Open

Paul C. Donaghy, Jahfer Hasoon, Calum A. Hamilton, Joanna Ciafone, Rory Durcan , et al. · 2025

Background Little is known about the prognostic value of plasma biomarkers in mild cognitive impairment with Lewy bodies (MCI‐LB). Objectives To investigate the association of four plasma biomarkers with disease progression in MCI. Methods…

Novel blood‐based proteomic signatures across multiple neurodegenerative diseases Open

Rory Durcan, Amanda Heslegrave, Peter Swann, Julia Goddard, Leonidas Chouliaras , et al. · 2025

INTRODUCTION Blood‐based biomarkers have the potential to support early and accurate diagnoses of neurodegenerative diseases, which are sensitive to molecular pathology and are predictive of outcome. We evaluated a novel multiplex proteomi…

Progression of clinical diagnostic features and cognitive decline in mild cognitive impairment with Lewy bodies Open

Calum A. Hamilton, Paul C. Donaghy, John‐Paul Taylor, Joanna Ciafone, Rory Durcan , et al. · 2025

Background Mild cognitive impairment with Lewy bodies (MCI-LB) may be identified prospectively based on the presence of cognitive impairment and several core clinical features (visual hallucinations, cognitive fluctuations, parkinsonism, a…

Novel blood-based proteomic signatures across multiple neurodegenerative diseases Open

Rory Durcan, Amanda Heslegrave, Peter Swann, Julia Goddard, Leonidas Chouliaras , et al. · 2024

INTRODUCTION Blood-based biomarkers have the potential to support early and accurate diagnosis of neurodegenerative diseases, which is sensitive to molecular pathology and predictive of outcome. We evaluated a novel multiplex proteomic met…

Substantia nigra and locus coeruleus microstructural abnormalities in isolated rapid eye movement sleep behaviour disorder and Parkinson’s disease Open

Jacopo Pasquini, Michael Firbank, Laura Best, Victoria Foster, Charlotte B. Stewart , et al. · 2024

Substantia nigra (SN) and locus coeruleus (LC) are two catecholaminergic, neuromelanin-rich nuclei that are affected in Parkinson’s disease (PD) and may show neuroimaging abnormalities before the onset of motor manifestations. The simultan…

Outcomes of Patients With Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease at 3 and 5 Years After Diagnosis Open

Calum A. Hamilton, Paul C. Donaghy, Rory Durcan, Joanna Ciafone, Kirsty Olsen , et al. · 2024

These findings support that prospectively identified probable MCI-LB is a prodromal presentation of DLB and that disease-specific classifications of MCI may reliably identify different prodromal dementias.

Identifying parkinsonism in mild cognitive impairment Open

Rishira Fernando, Alan Thomas, Calum A. Hamilton, Rory Durcan, Sally Barker , et al. · 2024

The five-item scale is effective to identify parkinsonism in MCI, but a lower threshold must be used in MCI compared with dementia.

Promises and Challenges of Blood Based Biomarkers of Alzheimer’s Disease and Neurodegeneration in Mild Cognitive Impairment: Importance of Non‐Alzheimer’s Aetiologies Open

Calum A. Hamilton, John T. O’Brien, Amanda Heslegrave, Rhiannon Laban, Paul C. Donaghy , et al. · 2023

Background Blood‐based biomarkers of Alzheimer’s disease (AD) may help to rule AD in, with particular promise at the mild cognitive impairment (MCI) stage when potential disease‐modifying treatments may be most effective. However, AD is no…

Serial Nigrostriatal Dopaminergic Imaging in Mild Cognitive Impairment With Lewy Bodies, Alzheimer Disease, and Age-Matched Controls Open

Rory Durcan, Gemma Roberts, Calum A. Hamilton, Paul C. Donaghy, Kim Howe , et al. · 2023

This study provides Class II evidence that longitudinal declines in striatal uptake measured using 123[I]-FP-CIT SPECT are associated with MCI due to Lewy body disease but not MCI due to Alzheimer disease.

Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies Open

Calum A. Hamilton, John T. O’Brien, Amanda Heslegrave, Rhiannon Laban, Paul C. Donaghy , et al. · 2023

Background Blood biomarkers of Alzheimer's disease (AD) may allow for the early detection of AD pathology in mild cognitive impairment (MCI) due to AD (MCI-AD) and as a co-pathology in MCI with Lewy bodies (MCI-LB). However not all cases o…

Clinical symptoms in mild cognitive impairment with Lewy bodies: Frequency, time of onset, and discriminant ability Open

Paul C. Donaghy, Calum A. Hamilton, Rory Durcan, Sarah Lawley, Sally Barker , et al. · 2023

Background and purpose Mild cognitive impairment with Lewy bodies (MCI‐LB) is associated with a range of cognitive, motor, neuropsychiatric, sleep, autonomic, and visual symptoms. We investigated the cumulative frequency of symptoms in a l…

Blood pressure and heart rate responses to orthostatic challenge and Valsalva manoeuvre in mild cognitive impairment with Lewy bodies Open

Calum A. Hamilton, James Frith, Paul C. Donaghy, Sally Barker, Rory Durcan , et al. · 2022

Objectives Orthostatic hypotension is a common feature of normal ageing, and age‐related neurodegenerative diseases, in particular the synucleinopathies including dementia with Lewy bodies. Orthostatic hypotension and other abnormal cardio…

A Longitudinal Study of Plasma <span>pTau181</span> in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease Open

Alan Thomas, Calum A. Hamilton, Amanda Heslegrave, Sally Barker, Rory Durcan , et al. · 2022

Background Alzheimer's disease (AD) co‐pathology is common in dementia with Lewy bodies and is associated with increased decline. Plasma pTau181 is a blood‐based biomarker that can detect AD co‐pathology. Objectives We investigated whether…

Assessment of autonomic symptoms may assist with early identification of mild cognitive impairment with Lewy bodies Open

Calum A. Hamilton, James Frith, Paul C. Donaghy, Sally Barker, Rory Durcan , et al. · 2022

Objectives Autonomic symptoms are a common feature of the synucleinopathies, and may be a distinguishing feature of prodromal Lewy body disease. We aimed to assess whether the cognitive prodrome of dementia with Lewy bodies, mild cognitive…

157 WHOLE HIPPOCAMPAL VOLUMES AND HIPPOCAMPAL SUBFIELD VOLUMES IN MCI-LB AND MCI-<span>ad</span> Open

Rory Durcan, Sean J. Colloby, Paul C. Donaghy, Sarah Lawley, John‐Paul Taylor , et al. · 2021

Background Mild cognitive impairment with Lewy bodies (MCI-LB) is the commonest prodromal phenotype of Dementia with Lewy Bodies (DLB) and may be challenging to differentiate from MCI due to Alzheimer’s disease (MCI-AD). Preservation of me…

Neuropsychological Impairments and Their Cognitive Architecture in Mild Cognitive Impairment (MCI) with Lewy Bodies and MCI-Alzheimer’s Disease Open

Joanna Ciafone, Alan Thomas, Rory Durcan, Paul C. Donaghy, Calum A. Hamilton , et al. · 2021

Objective: The present study aimed to clarify the neuropsychological profile of the emergent diagnostic category of Mild Cognitive Impairment with Lewy bodies (MCI-LB) and determine whether domain-specific impairments such as in memory wer…

Olfactory impairment in mild cognitive impairment with Lewy bodies and Alzheimer’s disease Open

Alan Thomas, Calum A. Hamilton, Sally Barker, Rory Durcan, Sarah Lawley , et al. · 2021

Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer’s disease Open

Julia Schumacher, Nicola J. Ray, Calum A. Hamilton, Paul C. Donaghy, Michael Firbank , et al. · 2021

Patients who have dementia with Lewy bodies and Alzheimer’s disease show early degeneration of the cholinergic nucleus basalis of Meynert. However, how white matter projections between the nucleus basalis of Meynert and the cortex are alte…

Slowing on quantitative EEG is associated with transition to dementia in mild cognitive impairment Open

Calum A. Hamilton, Julia Schumacher, Fiona E. Matthews, John‐Paul Taylor, Louise Allan , et al. · 2021

Electroencephalographic (EEG) abnormalities are greater in mild cognitive impairment (MCI) with Lewy bodies (MCI-LB) than in MCI due to Alzheimer's disease (MCI-AD) and may anticipate the onset of dementia. We aimed to assess whether quant…

Functional connectivity in mild cognitive impairment with Lewy bodies Open

Julia Schumacher, John‐Paul Taylor, Calum A. Hamilton, Michael Firbank, Paul C. Donaghy , et al. · 2021

Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies Open

Gemma Roberts, Rory Durcan, Paul C. Donaghy, Sarah Lawley, Joanna Ciafone , et al. · 2021

This study provides Class I evidence that cardiac MIBG distinguishes MCI-LB from MCI-AD.

Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease Open

Calum A. Hamilton, Fiona E. Matthews, Paul C. Donaghy, John‐Paul Taylor, John T. O’Brien , et al. · 2021

Diagnostic characteristics of Lewy body disease are associated with an increased risk of transition from mild cognitive impairment to dementia.

Hippocampal and insula volume in mild cognitive impairment with Lewy bodies Open

Michael Firbank, Rory Durcan, John T. O’Brien, Louise Allan, Sally Barker , et al. · 2021

Utility of the pareidolia test in mild cognitive impairment with Lewy bodies and Alzheimer's disease Open

Calum A. Hamilton, Fiona E. Matthews, Louise Allan, Sally Barker, Joanna Ciafone , et al. · 2021

Objectives Previous research has identified that dementia with Lewy bodies (DLB) has abnormal pareidolic responses which are associated with severity of visual hallucinations (VH), and the pareidolia test accurately classifies DLB with VH.…

In vivo nucleus basalis of Meynert degeneration in mild cognitive impairment with Lewy bodies Open

Julia Schumacher, John‐Paul Taylor, Calum A. Hamilton, Michael Firbank, Ruth Cromarty , et al. · 2021

Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies Open

Gemma Roberts, Paul C. Donaghy, Jim Lloyd, Rory Durcan, George Petrides , et al. · 2020

Background Dopaminergic imaging is an established biomarker for dementia with Lewy bodies, but its diagnostic accuracy at the mild cognitive impairment (MCI) stage remains uncertain. Aims To provide robust prospective evidence of the diagn…

Rory Durcan YOU? Author Swipe